Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 2/20 | 0.46 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367269 | 0.94 | SPPL2A (0.46) | BMP1SPPL2AABCB1LMNAMLNR | |
| SCHEMBL14113277 | 0.94 | SPPL2A (0.49) | BMP1SPPL2AABCB1LMNAMLNR | |
| SCHEMBL14367268 | 0.91 | ABCB1 (0.44) | SPPL2AABCB1LMNAMLNRABCB11 | |
| SCHEMBL14367270 | 0.89 | SPPL2A (0.49) | SPPL2AABCB1LMNAMLNRABCB11 | |
| SCHEMBL14367267 | 0.87 | SPPL2A (0.47) | SPPL2AABCB1LMNAMLNRABCB11 | |
| SCHEMBL6260340 | 0.85 | BMP1 (0.48) | BMP1LMNA | |
| SCHEMBL14338852 | 0.83 | SPPL2A (0.48) | SPPL2AABCB1LMNAMLNRABCB11 | |
| SCHEMBL5403915 | 0.83 | SPPL2A (0.53) | SPPL2AABCB1LMNAMLNRABCB11 | |
| SCHEMBL14338882 | 0.82 | SPPL2A (0.51) | SPPL2AABCB1LMNAMLNRABCB11 | |
| SCHEMBL12156760 | 0.81 | SPPL2A (0.64) | SPPL2AABCB1LMNAMLNRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | BMP1 3507/4885SPPL2A 636/4885ABCB1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.